Cetuximab Activity in Dysplastic Lesions of the Upper Aerodigestive Tract

BACKGROUND: High risk head and neck mucosal premalignancy has a malignant conversion rate of up to 40%, despite adequate surgical therapy. Epidermal Growth Factor Receptor (EGFR) blocking agents, including cetuximab, have shown activity in head and neck squamous cell carcinoma (HNSCC) and have poten...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oral Oncol
Hauptverfasser: Khan, Zubair, Epstein, Joel B, Marur, Shanthi, Gillespie, M Boyd, Feldman, Lawrence, Tsai, Hua-Ling, Zhang, Zhe, Wang, Hao, Sciubba, James, Ferris, Robert, Grandis, Jennifer R, Gibson, Michael, Koch, Wayne, Tufano, Ralph, Westra, William, Tsottles, Nancy, Ozawa, Hiroyuki, Chung, Christine, Califano, Joseph A
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7751887/
https://ncbi.nlm.nih.gov/pubmed/26686755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2015.11.016
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge